RMD vs. SMMT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at RMD and SMMT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | RMD | SMMT |
|---|---|---|
| Company Name | ResMed Inc. | Summit Therapeutics Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 36.01 billion USD | 12.96 billion USD |
| Exchange | NYSE | NasdaqGM |
| Listing Date | June 2, 1995 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of RMD and SMMT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | RMD | SMMT |
|---|---|---|
| 5-Day Price Return | -2.26% | -1.48% |
| 13-Week Price Return | -14.19% | -32.45% |
| 26-Week Price Return | -1.29% | -26.74% |
| 52-Week Price Return | 3.83% | -7.40% |
| Month-to-Date Return | -0.98% | -4.65% |
| Year-to-Date Return | 6.90% | 1.04% |
| 10-Day Avg. Volume | 1.39M | 2.53M |
| 3-Month Avg. Volume | 1.07M | 3.65M |
| 3-Month Volatility | 19.44% | 74.77% |
| Beta | 0.87 | -1.61 |
Profitability
Return on Equity (TTM)
RMD
25.13%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
In the upper quartile for the Health Care Equipment & Supplies industry, RMD’s Return on Equity of 25.13% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SMMT
-52.22%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
SMMT has a negative Return on Equity of -52.22%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
RMD
27.35%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
RMD’s Net Profit Margin of 27.35% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
SMMT
-9,027.08%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
SMMT has a negative Net Profit Margin of -9,027.08%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
RMD
33.18%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
RMD’s Operating Profit Margin of 33.18% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
SMMT
-8,108.33%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
SMMT has a negative Operating Profit Margin of -8,108.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | RMD | SMMT |
|---|---|---|
| Return on Equity (TTM) | 25.13% | -52.22% |
| Return on Assets (TTM) | 18.44% | -41.67% |
| Net Profit Margin (TTM) | 27.35% | -9,027.08% |
| Operating Profit Margin (TTM) | 33.18% | -8,108.33% |
| Gross Profit Margin (TTM) | 60.05% | -- |
Financial Strength
Current Ratio (MRQ)
RMD
2.89
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
RMD’s Current Ratio of 2.89 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
SMMT
3.80
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
SMMT’s Current Ratio of 3.80 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
RMD
0.11
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, RMD’s Debt-to-Equity Ratio of 0.11 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
SMMT
0.00
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
SMMT’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
RMD
661.20
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
With an Interest Coverage Ratio of 661.20, RMD demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
SMMT
-121.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
SMMT has a negative Interest Coverage Ratio of -121.35. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | RMD | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 2.89 | 3.80 |
| Quick Ratio (MRQ) | 1.87 | 3.68 |
| Debt-to-Equity Ratio (MRQ) | 0.11 | 0.00 |
| Interest Coverage Ratio (TTM) | 661.20 | -121.35 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
RMD
0.90%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Yield of 0.90% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
RMD
22.31%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Payout Ratio of 22.31% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | RMD | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.90% | 0.00% |
| Dividend Payout Ratio (TTM) | 22.31% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
RMD
24.87
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
RMD’s P/E Ratio of 24.87 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SMMT
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for SMMT is currently unavailable.
Price-to-Sales Ratio (TTM)
RMD
6.80
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
RMD’s P/S Ratio of 6.80 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
SMMT
13,285.76
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
With a P/S Ratio of 13,285.76, SMMT trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
RMD
6.53
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
RMD’s P/B Ratio of 6.53 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
SMMT
79.82
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
At 79.82, SMMT’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | RMD | SMMT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.87 | -- |
| Price-to-Sales Ratio (TTM) | 6.80 | 13,285.76 |
| Price-to-Book Ratio (MRQ) | 6.53 | 79.82 |
| Price-to-Free Cash Flow Ratio (TTM) | 20.36 | -- |